What's Coming to ASCO 2026: Sneak Peek at Transformative Cancer Research The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, schedul...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced p...
European Medicines Agency (EMA) has adopted a positive opinion recommending approval of nerandomilast for the treatment of idiopathic pulmonary fibrosis ...
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...
New Biacore 8S and Biacore 8S+ systems combine rapid screening and high-quality molecular characterization in a single system Biacore Insight So...
ProtaGene announced a strategic partnership with the Life Science business of Merck, which operates as MilliporeSigma in the United States and Canada, to...
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that it has received...
ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD ...
SERB Pharmaceuticals (“SERB”) and Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) announced that they have entered into an ...
LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company develo...
Hu-mAtrIx™-Enabled Next-Generation ACVR2A/2B-Targeting Antibody Demonstrates Potential to Become a Bes...
The launch follows Dr. Reddy’s receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company’s re...
Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating non-inferior efficacy of the Tok...
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Genera...
© 2026 Biopharma Boardroom. All Rights Reserved.
